Enanta Pharmaceuticals Inc ENTA
We take great care to ensure that the data presented and summarized in this overview for ENANTA PHARMACEUTICALS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ENTA
View all-
Farallon Capital Management LLC San Francisco, CA2.1MShares$25.3 Million0.17% of portfolio
-
Morgan Stanley New York, NY2.05MShares$24.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.93MShares$23.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.84MShares$22.2 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY1.24MShares$14.9 Million0.29% of portfolio
-
Krensavage Asset Management, LLC New York, NY1.12MShares$13.6 Million8.71% of portfolio
-
Marshall Wace, LLP London, X0951KShares$11.5 Million0.03% of portfolio
-
Northern Trust Corp Chicago, IL933KShares$11.3 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA854KShares$10.3 Million0.05% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny706KShares$8.52 Million0.01% of portfolio
Latest Institutional Activity in ENTA
Top Purchases
Top Sells
About ENTA
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
Insider Transactions at ENTA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 17
2024
|
Tara Lynn Kieffer Chief Product Strategy Officer |
SELL
Open market or private sale
|
Direct |
7,266
-18.35%
|
$87,192
$12.33 P/Share
|
|
Feb 26
2024
|
Nathaniel S. Gardiner Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,187
+6.41%
|
$41,496
$8.99 P/Share
|
|
Feb 12
2024
|
Tara Lynn Kieffer Chief Product Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
973
-2.4%
|
$11,676
$12.41 P/Share
|
|
Feb 12
2024
|
Tara Lynn Kieffer Chief Product Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,320
+7.56%
|
-
|
|
Feb 12
2024
|
Brendan Luu Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
973
-2.43%
|
$11,676
$12.41 P/Share
|
|
Feb 12
2024
|
Brendan Luu Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,320
+7.65%
|
-
|
|
Feb 12
2024
|
Scott T. Rottinghaus Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
755
-2.6%
|
$9,060
$12.41 P/Share
|
|
Feb 12
2024
|
Scott T. Rottinghaus Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,576
+8.15%
|
-
|
|
Feb 12
2024
|
Nathaniel S. Gardiner Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
973
-1.36%
|
$11,676
$12.41 P/Share
|
|
Feb 12
2024
|
Nathaniel S. Gardiner Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,320
+4.44%
|
-
|
|
Feb 12
2024
|
Yat Sun Or Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,080
-0.29%
|
$12,960
$12.41 P/Share
|
|
Feb 12
2024
|
Yat Sun Or Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,680
+0.97%
|
-
|
|
Feb 12
2024
|
Paul J Mellett Chief Fin. & Admin Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
973
-1.0%
|
$11,676
$12.41 P/Share
|
|
Feb 12
2024
|
Paul J Mellett Chief Fin. & Admin Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,320
+3.31%
|
-
|
|
Feb 12
2024
|
Jay R. Luly President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,584
-0.2%
|
$19,008
$12.41 P/Share
|
|
Feb 12
2024
|
Jay R. Luly President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
5,400
+0.66%
|
-
|
|
Dec 13
2023
|
Terry Vance Director |
SELL
Open market or private sale
|
Direct |
15,295
-72.51%
|
$137,655
$9.12 P/Share
|
|
Dec 05
2023
|
Brendan Luu Chief Business Officer |
SELL
Open market or private sale
|
Direct |
2,125
-5.47%
|
$19,125
$9.63 P/Share
|
|
Dec 05
2023
|
Nathaniel S. Gardiner Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,412
-3.42%
|
$21,708
$9.63 P/Share
|
|
Dec 05
2023
|
Tara Lynn Kieffer Chief Product Strategy Officer |
SELL
Open market or private sale
|
Direct |
2,125
-5.4%
|
$19,125
$9.63 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 24.9K shares |
|---|---|
| Exercise of conversion of derivative security | 5.19K shares |
| Payment of exercise price or tax liability | 19.4K shares |
|---|---|
| Open market or private sale | 41.8K shares |